PDCD1 and hepatocellular carcinoma: Finally, when combined with anti-PD1 therapy, STR-V-53 reprogrammed the T cell responses and prolonged medianoverall survival in an orthotopic HCC model in immunocompetent mice.More importantly, this combination resulted in durable responses in40% of the mice.